Nuvation sets its sights on Voranigo
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Nuvation takes the battle to Nuvalent
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
